- Home
- LTGO vs CLVT Comparison
LTGO vs CLVT Comparison
Compare LTGO & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTGO | CLVT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LTGO | CLVT |
|---|---|---|
| Price | $21.97 | $2.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.22 |
| AVG Volume (30 Days) | 292.6K | ★ 4.0M |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $974,345,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $17.22 | $1.66 |
| 52 Week High | $25.93 | $4.54 |
Technical Indicators
Market Signals| Indicator | LTGO | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 61.32 | 51.73 |
| Support Level | $18.46 | $1.83 |
| Resistance Level | $25.47 | $2.69 |
| Average True Range (ATR) | 1.87 | 0.11 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 46.72 | 67.74 |
Price Performance
Historical ComparisonAbout LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.